Ascend Capital’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Ascend Capital’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$2.35M	Buy	409,841 +110,146	+37%	+$630K	0.12%	126
2018 Q2	$1.5M	Sell	299,695 -201,883	-40%	-$1.04M	0.07%	152
2018 Q1	$2.57M	Sell	501,578 -65,251	-12%	-$393K	0.1%	154
2017 Q4	$3.41M	Buy	566,829 +167,643	+42%	+$1.01M	0.13%	148
2017 Q3	$2.22M	Buy	+399,186	New	+$2.06M	0.08%	137
2016 Q1	–	Sell	-41,611	Closed	-$337K	–	166
2015 Q4	$337K	Sell	41,611 -258,389	-86%	-$1.93M	0.01%	139
2015 Q3	$2.2M	Buy	300,000 +144,000	+92%	+$1.47M	0.09%	109
2015 Q2	$1.6M	Buy	156,000 +31,449	+25%	+$348K	0.05%	131
2015 Q1	$1.15M	Buy	+124,551	New	+$1.11M	0.04%	149

Other funds holding FOMX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Ascend Capital's FOMX Position: Q3 2018 in Review

Ascend Capital increased its Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) stake by 37% in Q3 2018, buying an estimated $630K and bringing the position to 409,841 shares worth $2.35M. The position accounts for 0.12% of the portfolio, ranked #126.

Ascend Capital first reported a position in FOMX in Q1 2015 and has held it in 9 quarters since. The position peaked at $3.41M in Q4 2017. 75 funds tracked by Wall St. Rank hold FOMX as of Q3 2018.

Ascend Capital held 409,841 shares of Foamix Pharmaceuticals Ltd. Ordinary Shares worth $2.35M as of Q3 2018.
Ascend Capital bought 110,146 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2018, an estimated $630K.
Foamix Pharmaceuticals Ltd. Ordinary Shares made up 0.12% of Ascend Capital's portfolio in Q3 2018, its #126 holding.
Ascend Capital first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q1 2015 and has held it in 9 quarters since.
Ascend Capital's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $3.41M in Q4 2017.
75 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.